BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 21707687)

  • 1. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
    Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
    Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
    Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method.
    Kim SY; Kim EK; Kwak JY; Moon HJ; Yoon JH
    Surgery; 2015 Feb; 157(2):354-61. PubMed ID: 25616949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
    Zatelli MC; Trasforini G; Leoni S; Frigato G; Buratto M; Tagliati F; Rossi R; Cavazzini L; Roti E; degli Uberti EC
    Eur J Endocrinol; 2009 Sep; 161(3):467-73. PubMed ID: 19574281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.
    Seo JY; Kim EK; Kwak JY
    Endocrine; 2014 Sep; 47(1):283-9. PubMed ID: 24452872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.
    Kwak JY; Kim EK; Kim JK; Han JH; Hong SW; Park TS; Choi JR
    Head Neck; 2010 Apr; 32(4):490-8. PubMed ID: 19672964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and predictive factors of inadequate fine-needle aspirates for BRAF(V600E) mutation analysis in thyroid nodules.
    Lee KH; Kim HS; Han BK; Ko EY; Ki CS; Shin JH
    AJR Am J Roentgenol; 2014 Feb; 202(2):391-6. PubMed ID: 24450682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between macrocalcification and papillary thyroid carcinoma and corresponding valuable diagnostic tool: retrospective study.
    Ye M; Wu S; Zhou Q; Wang F; Chen X; Gong X; Wu W
    World J Surg Oncol; 2023 May; 21(1):149. PubMed ID: 37194091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of
    Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
    Kim SK; Hwang TS; Yoo YB; Han HS; Kim DL; Song KH; Lim SD; Kim WS; Paik NS
    J Clin Endocrinol Metab; 2011 Mar; 96(3):658-64. PubMed ID: 21239517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the BRAF mutation analysis in calcified thyroid nodules.
    Yoo EY; Shin JH; Ko EY; Han BK
    AJR Am J Roentgenol; 2012 Apr; 198(4):891-5. PubMed ID: 22451557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.